Skip to main content
Cureus logoLink to Cureus
. 2022 Oct 29;14(10):e30852. doi: 10.7759/cureus.30852

Trimethoprim-Sulfamethoxazole-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Complicated by Acute Liver Failure

Naif Hindosh 1,, Ragarupa Kotala 1, Kristi Nguyen 1, Alpiniano Pintor 1
Editors: Alexander Muacevic, John R Adler
PMCID: PMC9705226  PMID: 36457619

Abstract

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a delayed adverse drug reaction that is characterized by fever, cutaneous manifestation, enlarged lymph nodes, hematologic abnormalities, and organ involvement. Multiple medications have been reported to cause DRESS with the presentation varying from drug to drug. Some cases are mild and can be managed by stopping the causative agent along with supportive measures; however, other cases can lead to multi-organ failure requiring systemic corticosteroids and organ transplant. Acute liver failure is a rare manifestation of DRESS. We report a patient who had recently completed a course of trimethoprim-sulfamethoxazole and presented with low-grade fever, diffuse skin rash, eosinophilia, elevated liver enzymes, acute kidney injury, and thrombocytopenia. DRESS was subsequently diagnosed based on history, physical examination, and relatively negative workup for an alternate diagnosis. The patient eventually showed improvement with steroid therapy without the need for a liver transplant. Due to its pharmacogenetic susceptibility, it is essential to recommend avoiding the causative medication for the patient's family members.

Keywords: regiscar, trimethoprim-sulfamethoxazole (tmp-smx), drug-induced acute liver failure, sulfa drug, bactrim ds, drug reaction with eosinophilia and systemic symptoms (dress)

Introduction

Drug-induced liver injury (DILI) is a well-known disease that accounts for the most common etiologies of acute liver failure in the United States [1]. Reported symptoms with DILI include fatigue, low-grade fever, loss of appetite, nausea, vomiting, right upper quadrant pain, jaundice, pruritus, or dark urine. In advanced stages, patients may develop encephalopathy and coagulopathy suggesting progression to acute liver failure [2]. Most common medications that are involved in DILI are acetaminophen, anesthetics, non-steroidal anti-inflammatory drugs (NSAIDs), statins, herbals, and antimicrobial agents such as isoniazid, B-lactams, sulfonamides, in addition to antifungals and HIV antiretroviral therapy [3].

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a serious delayed adverse drug reaction that manifests as severe cutaneous lesions and multi-organ failure with associated fever, hematologic abnormalities, and lymphadenopathy [4]. The clinical presentation usually appears two to six weeks from the time of exposure to the causative agent [5]. DRESS has a mortality rate of 10%, with most cases usually secondary to hepatic involvement with resultant fulminant hepatitis [6]. The most reported causative agents of this syndrome are antiepileptic drugs, allopurinol, sulfonamides, and antibiotics such as vancomycin, minocycline, ampicillin, and sulfamethoxazole-trimethoprim [7]. The best-used criteria for the diagnosis of this syndrome are based on the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) scoring system [7].

Trimethoprim-sulfamethoxazole (TMP-SMX), is a commonly used antimicrobial agent for prophylaxis and treatment purposes. It has a wide range of side effects including gastrointestinal symptoms, dermatological reactions, kidney injury, and hepatic toxicity [8]. 

We present a case of a 57-year-old male patient with acute liver failure in the setting of DRESS syndrome secondary to the recent use of TMP-SMX.

Case presentation

A 57-year-old male of Asian descent presented with two weeks of complaints of intermittent fever, fatigue, and painless rash. He underwent surgical resection of inverted sinus papilloma and was prescribed a 14-day course of TMP-SMX six weeks before the presentation. He denied weight loss, night sweats, sore throat, cough, shortness of breath, chest pain, nausea, vomiting, diarrhea, abdominal pain, arthralgia, myalgia, hematuria, headache, and confusion. Vital signs were stable with the exception of a temperature of 100.4F. Physical exam was notable for icteric sclerae, jaundiced skin, and a diffuse purpuric rash, which was more prominent over all extremities with desquamation, without oral, ocular, or genital involvements. No lymphadenopathy was present in the cervical, axillary, or inguinal regions. Abdominal examination was benign with no hepatosplenomegaly. Neurological examination was completely normal. The patient denied recent travel, alcohol consumption, and illegal drug use. The initial laboratory workup is shown in Table 1.

Table 1. Laboratory workup results on admission.

WBC: white blood count; BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; INR: international normalized ratio; PT: prothrombin time; PTT: partial thromboplastin time.

Test Value Reference range
Hemoglobin 10.9 12-17 g/dL
WBC 9.56 4.31-10.16 Thousand/uL
Eosinophils % 29% 0-6%
Absolute eosinophils 2.77 0-0.4 Thousand/uL
Lymphocytes 11% 14-44%
Platelets 1 149-390 Thousand/uL
Sodium 136 136-145 mmol/L
Potassium 4.7 3.5-5.3 mmol/L
Chloride 102 100-108 mmol/L
BUN 20 5-25 mg/dL
Creatinine 2.51 (baseline 1) 0.6-1.3 mg/dL
Calcium 8.4 8.3-10.1 mg/dL
eGFR 27  
ALT 376 12-78 U/L
AST 283 5-45 U/L
ALP 1476 46-115 U/L
Total bilirubin 20.5 0.2-1 mg/dL
Direct bilirubin 15.68 0-0.2 mg/dL
Total protein 6.6 6.4-8.2 g/dL
Albumin 2.50 3.5-5 g/dL
INR 1.20 0.84-1.19
PT 15.2 seconds 11.6-14.5 seconds
PTT 38 seconds 17-27 seconds

The patient received platelet transfusion and was started on intravenous hydration and empiric intravenous broad-spectrum antibiotics. The infectious workup was negative for a tickborne disease, parasite infection, coronavirus disease 2019 (COVID-19), HIV, Ebstein-Barr virus (EBV), cytomegalovirus (CMV), hepatitis, A, B, and C infections. Two sets of blood cultures were negative as well. C-reactive protein and erythrocyte sedimentation rate (ESR) were slightly elevated; however, autoimmune workup including antinuclear antibody (ANA), anti-double-stranded DNA antibodies, antimitochondrial antibody (AMA), anti-smooth muscle antibody (ASMA), antineutrophil cytoplasmic antibodies (ANCA), creatine kinase, and C3 and C4 complements were all within normal range. Hematology workup was negative for hemolytic etiology, hemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), and disseminated intravascular coagulation (DIC). The peripheral smear results were unremarkable with no parasites noted on the parasite smear. Flow cytometry results were of no significance. Further testing showed normal acetaminophen, ceruloplasmin, and alfa antitrypsin levels with slightly elevated ferritin level. The urine drug screen was negative. Abdominal ultrasound and computed tomography scan were unremarkable. Liver Doppler ultrasound demonstrated patent hepatic vasculature. A liver biopsy was not performed due to severe thrombocytopenia. 

With no clear cause for the patient's presentation, the etiology was felt to be drug-induced due to TMP-SMX. Further history was obtained and the patient reported that his mother and brother had a history of severe reactions to TMP-SMX.

As infectious etiology was ruled out along with continuous worsening liver functions as shown in Table 2, antibiotics were stopped and intravenous methylprednisolone was started. The patient was then transferred to the liver transplant center. 

Table 2. Laboratory workup on hospital day 4.

WBC: white blood count; eGFR: estimated glomerular filtration rate; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; INR: international normalized ratio; PT: prothrombin time; PTT: partial thromboplastin time.

Test Value Reference range
Hemoglobin 8.8 12-17 g/dL
WBC 16.6 4.31-10.16 Thousand/uL
Eosinophils % 33% 0-6%
Atypical lymphocytes 3% 0%
Platelets 13 149-390 Thousand/uL
Creatinine 1.24 0.60-1.3 mg/dL
eGFR 64  
ALT 3303 12-78 U/L
AST 955 5-45 U/L
ALP 1616 46-115 U/L
Total bilirubin 22.19 0.2-1 mg/dL
Direct bilirubin 17.56 0-0.2 mg/dL
Total protein 4.4 6.4-8.2 g/dL
Albumin 1.8 3.5-5 g/dL
INR 1.96 0.84-1.19
PT 22.1 seconds 11.6-14.5 seconds
PTT 33.3 seconds 17-37 seconds

While the patient was undergoing liver transplant evaluation, fortunately, his laboratory testing started to improve as shown in Table 3. He did not require the transplant eventually. The rash was completely resolved and he was discharged on a prednisone taper. 

Table 3. Laboratory workup results within two weeks of starting steroid therapy.

WBC: white blood count; eGFR: estimated glomerular filtration rate; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; INR: international normalized ratio; PT: prothrombin time; PTT: partial thromboplastin time.

Test Value Reference range
Hemoglobin 10.3 12-17 g/dL
WBC 18 4.31-10.16 Thousand/uL
Eosinophils % 16% 0-6%
Atypical lymphocytes 0% 0%
Platelets 163 149-390 Thousand/uL
Creatinine 1.08 0.6-1.3 mg/dL
eGFR 60  
ALT 226 12-78 U/L
AST 56 5-45 U/L
ALP 598 46-115 U/L
Total bilirubin 11.8 0.2-1 mg/dL
Direct bilirubin 9.1 0-0.2 mg/dL
Total protein 4.8 6.4-8.2 g/dL
Albumin 1.8 3.5-5 g/dL
INR 1 0.84-1.19
PT 12.3 seconds 11.6-14.5 seconds

The patient continued to have close follow-ups with his primary care provider and hepatologist. His laboratory tests three months after discharge showed continuous improvement in liver functions as shown in Table 4.

Table 4. Laboratory tests three months after discharge from the hospital.

WBC: white blood count; eGFR: estimated glomerular filtration rate; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; INR: international normalized ratio

Test Value Reference range
Hemoglobin 13.8 12-17 g/dL
WBC 6.95 4.31-10.16 Thousand/uL
Eosinophils % 0% 0-6%
Atypical lymphocytes 0% 0%
Platelets 186 149-390 Thousand/uL
Creatinine 1.12 0.60-1.30 mg/dL
eGFR 63  
ALT 99 12-78 U/L
AST 56 5-45 U/L
ALP 269 46-115 U/L
Total bilirubin 7.9 0.2-1 mg/dL
Direct bilirubin 4.1 0-0.2 mg/dL
INR 0.93 0.84-1.19

Discussion

The incidence of DRESS is estimated to be one in every 1000-10000 exposures [9,10]. DRESS reaction is suggested to be mediated by T-cell hypersensitivity [11]. Antibiotics attribute to 74% of DRESS cases, and sulfonamides compromised 3% of the cases [9]. The sulfonamide component of TMP-SMX is the most common culprit of liver injury, which may manifest as cholestatic, hepatocellular, or mixed [12]. 

Patients who have slow acetylation are more prone to delayed hypersensitivity reactions. Two major metabolisms of sulfonamides reported are through N-acetylation and oxidation pathway by cytochrome P450. N-acetyltransferase levels invariably differed in slow acetylators, in most of the patients the enzyme was genetically determined. Slow acetylators utilize the cytochrome P450 pathway to metabolize sulfonamides. They generate more toxic metabolites such as hydroxylamines or nitroso causing cell death or more immunologic phenomena like DRESS. They are detoxified partially by conjugation with glutathione. The incidence of slow acetylators is 5-10% for Asian descendants [13,14].

DRESS was subsequently diagnosed based on history, physical examination, and relatively negative workup for alternate diagnoses such as viral infection, autoimmune disease, hemolytic etiology, or lymphoma. Other cutaneous adverse drug reactions such as Steven-Johnson syndrome (SJS), exanthematous drug reaction, or acute generalized exanthematous pustulosis (AGEP) were excluded based on the rash characteristics, degree of eosinophilia, the severity of visceral organ involvement, and the absence of oral, genital, and ocular involvement.

RegiSCAR scoring system has been utilized to help in confirming or excluding the diagnosis of DRESS [12]. Our patient had a score of 6, which highly suggested the diagnosis of DRESS. This is shown in Table 5.

Table 5. Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) scoring system.

Total score:  <2: Excluded ; 2-3: Possible ; 4-5:Probable;  ≥6: Definite

BSA: body surface area; HAV: hepatitis A virus; HBV: hepatitis B virus; HCV: hepatitis C virus; ANA: antinuclear antibodies

Item -1 0 +1 Additional points Our patient
Fever >101.3F No Yes     -1
Enlarged lymph node >1cm   No Yes   0
Eosinophilia ≥0.7 × 109   No Yes 2 points if >1.5 x 109 2
Atypical lymphocytes   No Yes   1
Rash suggestive of DRESS: => facial edema, purpura, infiltration, desquamation. No Unknown Yes   1
Extent ≥50% of BSA   No/Unkown Yes   1
Skin biopsy suggestive of DRESS No Yes/Unknown     0
Organ involvement: 1 point for each organ involvement.   No Yes maximum score: 2 1
Disease duration ≥15 days No/Unknown Yes     0
Exclusion of other causes; add 1 point if 3 of the following tests are excluded: HAV, HBV, HCV, mycoplasma, chlamydia, ANA, blood culture.   No/Unknown Yes   1
Final score         6

Treatment includes stopping the causative drug along with supportive therapy. Systemic glucocorticoids have been utilized in severe cases with organ involvement. Literature showed mixed outcomes in terms of using steroids in DRESS-induced liver injury. Two multicenter retrospective studies by Ichai et al. [15] and Lee et al. [16] concluded that glucocorticoid had no significance in improving DRESS-induced liver failure; however, other studies demonstrated better outcomes in similar cases when managed with extensive steroid therapy [12,17]. The study by Ichai et al. also demonstrated that seven out of 16 patients required liver transplants [15]. Our patient responded well to intravenous methylprednisolone therapy and prolonged prednisone taper. 

In terms of prognosis, complete recovery can take up to 12 weeks after stopping the offending drug [18,19]. It had been reported that patients who recover from DRESS, may develop a variety of autoimmune conditions [20,21 ]. CMV reactivation had been associated with the worst outcomes [22]. Even after full recovery, it has been shown that DRESS flare-up is a possibility and is more likely to be linked with patients who required systemic corticosteroid therapy during the acute event or had rapid prednisone taper [18,23].

Conclusions

The presentation of DRESS is heterogenous and may lead to multiorgan failure. It is important to recommend avoiding the causative medications for the patient's family members as there is a link between several human leukocyte antigen (HLA) haplotypes and the probability of developing DRESS. Monitoring for developing autoimmune diseases is an essential part of follow-up management. Stopping the offending drug is the mainstay of treatment. Steroid therapy has been used in severe cases with organ involvement. Acute liver failure induced by DRESS can be reversible and liver transplant can be avoidable. 

The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

The authors have declared that no competing interests exist.

Human Ethics

Consent was obtained or waived by all participants in this study

References

  • 1.Drug-induced liver injury. Katarey D, Verma S. Clin Med (Lond) 2016;16:0–9. doi: 10.7861/clinmedicine.16-6s-s104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Drug-induced liver injury. David S, Hamilton JP. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160634/ US Gastroenterol Hepatol Rev. 2010;6:73–80. [PMC free article] [PubMed] [Google Scholar]
  • 3.Drug-induced liver disease. Davern TJ. Clin Liver Dis. 2012;16:231–245. doi: 10.1016/j.cld.2012.03.002. [DOI] [PubMed] [Google Scholar]
  • 4.Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS) Bocquet H, Bagot M, Roujeau JC. https://pubmed.ncbi.nlm.nih.gov/9069593/ Semin Cutan Med Surg. 1996;15:250–257. doi: 10.1016/s1085-5629(96)80038-1. [DOI] [PubMed] [Google Scholar]
  • 5.Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review. Sharifzadeh S, Mohammadpour AH, Tavanaee A, Elyasi S. Eur J Clin Pharmacol. 2021;77:275–289. doi: 10.1007/s00228-020-03005-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.DRESS syndrome: Part I. Clinical perspectives. Husain Z, Reddy BY, Schwartz RA. https://www.sciencedirect.com/science/article/abs/pii/S0190962213001540. J Am Acad Dermatol. 2013;68:693–614. doi: 10.1016/j.jaad.2013.01.033. [DOI] [PubMed] [Google Scholar]
  • 7.Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Br J Dermatol. 2013;169:1071–1080. doi: 10.1111/bjd.12501. [DOI] [PubMed] [Google Scholar]
  • 8.Sulfamethoxazole/trimethoprim induced liver failure: a case report. Abusin S, Johnson S. Cases J. 2008;1:44. doi: 10.1186/1757-1626-1-44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome identified in the electronic health record allergy module. Wolfson AR, Zhou L, Li Y, Phadke NA, Chow OA, Blumenthal KG. J Allergy Clin Immunol Pract. 2019;7:633–640. doi: 10.1016/j.jaip.2018.08.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Drug hypersensitivity syndrome in a West-Indian population. Muller P, Dubreil P, Mahé A, Lamaury I, Salzer B, Deloumeaux J, Strobel M. https://www.jle.com/fr/revues/ejd/e-docs/drug_hypersensitivity_syndrome_in_a_westindian_population__260528/article.phtml?cle_doc=0003F9B0. Eur J Dermatol. 2003;13:478–481. [PubMed] [Google Scholar]
  • 11.Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome due to vancomycin. Kulkarni MP, Chinta S, Sosa F, Nasr R, Kelly P. Cureus. 2022;14:0. doi: 10.7759/cureus.26219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome. Martinez-Cabriales SA, Shear NH, Gonzalez-Moreno EI. World J Clin Cases. 2019;7:705–716. doi: 10.12998/wjcc.v7.i6.705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Severe sulfonamide hypersensitivity reaction in a slow acetylator patient. Yap RL, Mermel LA. https://journals.lww.com/infectdis/fulltext/2001/12000/severe_sulfonamide_hypersensitivity_reaction_in_a.8.aspx Infect Dis Clin Pract (Baltim Md) 2001;10:493–495. [Google Scholar]
  • 14.Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Clin Pharmacol Ther. 1991;49:13–17. doi: 10.1038/clpt.1991.3. [DOI] [PubMed] [Google Scholar]
  • 15.Acute liver failure/injury related to drug reaction with eosinophilia and systemic symptoms: outcomes and prognostic factors. Ichai P, Laurent-Bellue A, Saliba F, et al. Transplantation. 2017;101:1830–1837. doi: 10.1097/TP.0000000000001655. [DOI] [PubMed] [Google Scholar]
  • 16.Characteristics of liver injury in drug-induced systemic hypersensitivity reactions. Lee T, Lee YS, Yoon SY, et al. J Am Acad Dermatol. 2013;69:407–415. doi: 10.1016/j.jaad.2013.03.024. [DOI] [PubMed] [Google Scholar]
  • 17.Favourable issue of a fulminant hepatitis associated with sulfasalazine DRESS syndrome without liver transplantation. Descloux E, Argaud L, Dumortier J, Scoazec JY, Boillot O, Robert D. Intensive Care Med. 2005;31:1727–1728. doi: 10.1007/s00134-005-2846-3. [DOI] [PubMed] [Google Scholar]
  • 18.Prolonged evolution of drug reaction with eosinophilia and systemic symptoms: clinical, virologic, and biological features. Tetart F, Picard D, Janela B, Joly P, Musette P. JAMA Dermatol. 2014;150:206–207. doi: 10.1001/jamadermatol.2013.6698. [DOI] [PubMed] [Google Scholar]
  • 19.The DRESS syndrome: a literature review. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC. Am J Med. 2011;124:588–597. doi: 10.1016/j.amjmed.2011.01.017. [DOI] [PubMed] [Google Scholar]
  • 20.Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. Chen YC, Chang CY, Cho YT, Chiu HC, Chu CY. J Am Acad Dermatol. 2013;68:459–465. doi: 10.1016/j.jaad.2012.08.009. [DOI] [PubMed] [Google Scholar]
  • 21.Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. Ushigome Y, Kano Y, Ishida T, Hirahara K, Shiohara T. J Am Acad Dermatol. 2013;68:721–728. doi: 10.1016/j.jaad.2012.10.017. [DOI] [PubMed] [Google Scholar]
  • 22.Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score: A useful tool for assessing disease severity and predicting fatal cytomegalovirus disease. Mizukawa Y, Hirahara K, Kano Y, Shiohara T. J Am Acad Dermatol. 2019;80:670–678. doi: 10.1016/j.jaad.2018.08.052. [DOI] [PubMed] [Google Scholar]
  • 23.Therapeutic management of DRESS: a retrospective study of 38 cases. Funck-Brentano E, Duong TA, Bouvresse S, et al. J Am Acad Dermatol. 2015;72:246–252. doi: 10.1016/j.jaad.2014.10.032. [DOI] [PubMed] [Google Scholar]

Articles from Cureus are provided here courtesy of Cureus Inc.

RESOURCES